// App-Quantinova.ai

: Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer.

Researchers

Presenter

  • David H Aggen

Principal Investigators

  • Jeffrey Melson Clarke

  • Adam Steven Asch

  • Emiliano Calvo

  • Jon Zugazagoitia

  • Marcus O. Butler

  • Victor Moreno

  • Andres Cervantes

  • Brian Andrew Van Tine

  • Donald P. Lawrence

  • Melissa Lynne Johnson

  • Francine Elizabeth Brophy

  • Robyn Broad

  • Martin Isabelle

  • Alasdair Gunn

  • Jean-Marc Navenot

  • Jose Saro

  • Elliot Norry

  • John A. Charlson

Medical Centers

  • Adaptimmune, Philadelphia, PA

  • Duke Cancer Center, Durham, NC

  • Washington University School of Medicine, St. Louis, MO

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Stephenson Cancer Center at Oklahoma University Health Sciences, Oklahoma City, OK

  • Massachusetts General Hospital, Boston, MA

  • Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain

  • Adaptimmune, Abingdon, United Kingdom

  • Sarah Cannon Research Institute, Nashville, TN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain

  • Biomedical Research Institute INCLICA, University of Valencia, Valencia, Spain

Locations

  • Canada

  • United Kingdom

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • T-cell receptor

Drug/Treatment

  • Surpass Cream

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT04044859

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved